Arcus Biosciences, Inc.
RCUS
$19.72
-$0.47-2.33%
NYSE
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -83.75% | 471.43% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -83.75% | 471.43% | |||
| Cost of Revenue | 1.44% | 13.93% | |||
| Gross Profit | -647.62% | 122.34% | |||
| SG&A Expenses | -6.90% | 3.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.00% | 12.00% | |||
| Operating Income | -1,675.00% | 93.44% | |||
| Income Before Tax | -- | 100.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -- | 100.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -- | 100.00% | |||
| EBIT | -1,675.00% | 93.44% | |||
| EBITDA | -2,233.33% | 94.96% | |||
| EPS Basic | -11.37% | 0.00% | |||
| Normalized Basic EPS | -- | 100.00% | |||
| EPS Diluted | -11.37% | 0.00% | |||
| Normalized Diluted EPS | -- | 100.00% | |||
| Average Basic Shares Outstanding | 0.38% | 7.83% | |||
| Average Diluted Shares Outstanding | 0.00% | 8.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||